He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.
The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.
Just as we’ve seen the entire healthcare landscape change in 2020 because of COVID-19, the world of biosimilars is ever-changing.
Residents and staff have been hit hard by the disease. PPE is in short supply. The deaths are taking an emotional toll on largely unheralded workers.
Why are so few biosimilars approved and on the market in the U.S.?
How are healthcare systems addressing the shift from inpatient to observation?
How to appeal to people of any age.
Healthcare executives and consultants told us which strategic trends to look out for — before COVID-19.
As president and CEO of Cancer Treatment Centers of America, Pat A. Basu, MD, MBA, looks to transform, improve, and influence cancer care on a large scale.